A blood-based 7-metabolite signature for the early diagnosis of Alzheimer’s disease

Miguel Calero¹, Alberto Rábano², Andrés Rodríguez-Martín³, Luis Gil-de-Gómez³, Meritxell Valenti-Soler², Juan Marín Muñoz⁴, Ana Frank García⁵, Lorenzo Morlán Gracia⁶, María Concepción Guisasola Zulueta⁷, Félix Bermejo-Pareja⁸, David A. Pérez-Martínez⁹ and Javier Olázarán⁰

¹Chronic Disease Programme, CIBERNED and Alzheimer Disease Research Unit, CIEN Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid (Spain). ²CIBERNED, Carlos III Institute of Health, Alzheimer Center Reina Sofia Foundation, Madrid (Spain). ³BIOCROSS, S.L., Valladolid (Spain). ⁴Hospital Clínico Universitario Virgen de la Arrixaca de Murcia, Unidad de demencias, Murcia (Spain). ⁵IdiPaz Hospital Universitario La Paz, Madrid (Spain). ⁶Hospital Universitario de Getafe (Spain). ⁷ HGU Gregorio Marañón, Madrid (Spain). ⁸Head Neurology Department U. H. “12 de Octubre”, Madrid (Spain), CIBERNED, Carlos III National Research Institute, Madrid (Spain), Associate Professor of the Medicine Department, Complutense University, Madrid (Spain). ⁹Hospital Universitario Infanta Cristina, Sección de Neurología, Parla-Madrid (Spain). ¹⁰Servicio de Neurología, HGU Gregorio Marañón, Alzheimer Center Reina Sofia Foundation–CIEN Foundation, Madrid (Spain).

Summary

Accurate blood-based biomarkers of Alzheimer’s disease (AD) could provide a simple, inexpensive and non-invasive means of diagnosing AD and monitoring disease progression over time, circumventing the many problems associated with the analysis of CSF, the current diagnostic sample of choice. We sought to develop a robust AD biomarker panel by identifying alterations in plasma metabolites that persist throughout the continuum of AD pathophysiology. Using a multicenter, cross-sectional study design, we based our analysis on metabolites whose levels were altered both in AD patients and in patients with amnestic mild cognitive impairment (aMCI), the earliest clinical manifestation of AD. The resulting 7-metabolite biomarker panel accurately distinguishes AD and aMCI patients from normal cognition controls, and thus constitutes a potentially useful tool for the early diagnosis of AD.

Materials and Methods

Ultra performance liquid chromatography coupled to mass spectrometry (UPLC-MS) was used to independently compare the levels of 495 plasma metabolites in aMCI (n=58) and AD (n=100) patients with those of normal cognition controls (NC, n=93). Three separate UPLC-MS platforms were used to ensure optimal metabolite profiling (Fig. 1). Metabolites whose levels were altered in both AD and aMCI patients with respect to NC were selected and used to generate a logistic regression model that accurately distinguished AD from NC patients.

Results

We identified 44 metabolites whose levels were significantly altered (p <0.05) in both aMCI and AD patients (Fig. 2a). These metabolites were used as independent variables to build a multivariate diagnostic algorithm based on a logistic regression model using cross-validation of data. We next developed a classification rule to distinguish the NC from the AD group, the more homogeneous and better diagnosed of the two patient groups. Iterative logistic regression models assuming stepwise selection were used to generate the final 7-metabolite model, which consisted of three amino acids (glutamic acid, alanine and aspartic acid), one non-esterified fatty acid (22:6n-3, DHA), one bile acid (deoxycortic acid), one phosphatidylethanolamine (PE[36:4]) and one sphingomyelin (SM[39:1]) (Fig. 2b). The final model accurately distinguished AD patients from NC controls (AUC, 0.918). Importantly, the model also distinguished aMCI patients from NC controls (AUC, 0.826), supporting its potential diagnostic utility in early disease stages (Fig. 2c). Detailed analysis ruled out the influence of potential confounding variables, including comorbidities and treatments, on each of the seven biomarkers included in the final model (data not shown).

Conclusions

Our findings describe a robust and sensitive biomarker panel that accurately distinguishes AD patients from normal cognition controls, even in early disease stages. This panel constitutes an important tool for the early identification of AD pathophysiology through the analysis of plasma samples.

www.biocrossdiagnostico.com